Summary

for people ages 18-85 (full criteria)
at Irvine, California and other locations
study started
estimated completion

Description

Summary

A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.

Official Title

A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis.

Keywords

Non-infectious Anterior UveitisUveitisUveitis, AnteriorIridocyclitisPharmaceutical SolutionsOphthalmic SolutionsADX-102 Ophthalmic Solution (0.5%)Vehicle of ADX-102 Ophthalmic Solution

Eligibility

You can join if…

Open to people ages 18-85

  • Male or female subjects aged ≥ 18 years and ≤ 85 years.
  • Subjects with acute non-infectious anterior uveitis with onset of symptoms within the previous 2 weeks.
  • Best corrected visual acuity (BCVA) better than or equal to 35 letters in the study eye and 65 letters in the non-study eye using ETDRS testing.

You CAN'T join if...

  • Have severe/serious ocular pathology in the study eye(s) which may preclude study completion, in the judgement of the Investigator.
  • Active intermediate or posterior uveitis in the study eye(s).
  • Previous anterior uveitis episode in the study eye ≤ 4 weeks prior to screening.
  • Have participated in another investigational device or drug study within 30 days prior to screening.
  • Participation in a prior ADX-102 study.

Locations

  • University of California, Irvineaccepting new patients
    IrvineCalifornia92697United States
  • Retina-Vitreous Associates Medical Groupaccepting new patients
    Beverly HillsCalifornia90211United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Aldeyra Therapeutics, Inc.
ID
NCT03131154
Phase
Phase 3
Study Type
Interventional
Last Updated